Classical blood biomarkers identify patients with higher risk for relapse 6 
months after alcohol withdrawal treatment

Raabe, Florian J.; Wagner, Elias; Weiser, Judith; Brechtel, Sarah; Popovic, David; Adorjan, Kristina; Pogarell, Oliver; Hoch, Eva; Koller, Gabriele

doi:10.1007/s00406-020-01153-8

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Classical blood biomarkers identify patients with higher risk for relapse 6 months after alcohol withdrawal treatment

MPS-Authors

/persons/resource/persons186223

Raabe, Florian J.
IMPRS Translational Psychiatry, Max Planck Institute of Psychiatry, Max Planck Society;

/persons/resource/persons262425

Popovic, David
IMPRS Translational Psychiatry, Max Planck Institute of Psychiatry, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Raabe, F. J., Wagner, E., Weiser, J., Brechtel, S., Popovic, D., Adorjan, K., et al. (2021). Classical blood biomarkers identify patients with higher risk for relapse 6 months after alcohol withdrawal treatment. EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 271(5), 891-902. doi:10.1007/s00406-020-01153-8.

Cite as: https://hdl.handle.net/21.11116/0000-0008-DB9B-3

Abstract

This naturalistic study among patients with alcohol dependence examined whether routine blood biomarkers could help to identify patients with high risk for relapse after withdrawal treatment. In a longitudinal study with 6-month follow-up among 133 patients with alcohol dependence who received inpatient alcohol withdrawal treatment, we investigated the usefulness of routine blood biomarkers and clinical and sociodemographic factors for potential outcome prediction and risk stratification. Baseline routine blood biomarkers (gamma-glutamyl transferase [GGT], alanine aminotransferase [ALT/GPT], aspartate aminotransferase [AST/GOT], mean cell volume of erythrocytes [MCV]), and clinical and sociodemographic characteristics were recorded at admission. Standardized 6 months' follow-up assessed outcome variables continuous abstinence, days of continuous abstinence, daily alcohol consumption and current abstinence. The combined threshold criterion of an AST:ALT ratio > 1.00 and MCV > 90.0 fl helped to identify high-risk patients. They had lower abstinence rates (P = 0.001), higher rates of daily alcohol consumption (P < 0.001) and shorter periods of continuous abstinence (P = 0.027) compared with low-risk patients who did not meet the threshold criterion. Regression analysis confirmed our hypothesis that the combination criterion is an individual baseline variable that significantly predicted parts of the respective outcome variances. Routinely assessed indirect alcohol biomarkers help to identify patients with high risk for relapse after alcohol withdrawal treatment. Clinical decision algorithms to identify patients with high risk for relapse after alcohol withdrawal treatment could include classical blood biomarkers in addition to clinical and sociodemographic items.